A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2D3

Journal of Bone and Mineral Research

Volumn 14, Issue 9, 1999, Pages 1478-1485

  Morony, Sean ^a   Capparelli, Casey ^a   Richard, Lee ^a   Shimamoto, Grant ^a   Boone, Thomas ^a   Lacey, David L ^a   Dunstan, Colin R ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; INTERLEUKIN 1BETA; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; HYPERCALCEMIA; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; WEIGHT REDUCTION;

ANIMALS; BONE AND BONES; BONE RESORPTION; CALCITRIOL; CALCIUM; CELL COUNT; GLYCOPROTEINS; HUMANS; HYPERCALCEMIA; INTERLEUKIN-1; ISOMERISM; MALE; MICE; OSTEOCLASTS; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN; PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 0032860576     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1999.14.9.1478     Document Type: Article

References (40)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luethy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
2. Yasuda H, Shima N, Nakagawa N, Mochizuki S, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337.
3. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu WL, Lacey DL, Boyle WJ, Simonet WS 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268.
4. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
5. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FSr, Frankel WN, Lee SY, Choi Y 1997 TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:25190-25194.
6. Anderson DM, Maraskovsky EWLB, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179.
7. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
8. Yamamoto M, Murakami T, Nishikawa M, Tsuda E, Mochizuki S-I, Higashio K, Akatsu T, Motoyoshi K, Nagata N 1998 Hypocalcemic effect of osteoclastogensis inhibitory factor/ osteoprotegerin in the thyroparathyroidectomized rat. Endocrinology 139:4012-4015.
9. Collip JB 1925 Extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J Biol Chem 63:395-438.
10. Parfitt AM 1976 The action of parathyroid hormone on bone: Relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease, Parts I-IV. Metabolism 25:809-844, 909-959, 1033-1069, 1157-1188.
11. Fukayama S, Bosma TJ, Goad DL, Voelkel EF, Tashjian AHJ 1988 Human parathyroid hormone (PTH)-related protein and human PTH: Comparative biological activities on human bone cells and bone resorption. Endocrinology 123:2841-2848.
12. Yates AJ, Gutierrez GE, Smolens P, Travis PS, Katz MS, Aufdemorte TB, Boyce BF, Hymer TK, Poser JW, Mundy GR 1988 Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents. J Clin Invest 81:932-938.
13. Norman AW 1979 Vitamin D metabolism and calcium adsorption. Am J Med 67:989-998.
14. 3 in bones from fetal rats. Calcif Tissue Int 35:177-182.
15. Thomson BM, Mundy GR, Chambers TJ 1987 Tumor necrosis factors alpha and beta induce osteoclastic bone resorption. J Immunol 138:775-779.
16. Lerner UH, Ohlin A 1993 Tumor necrosis factors alpha and beta can stimulate bone resorption in cultured mouse calvariae by a prostaglandin-independent mechanism. J Bone Miner Res 8:147-155.
17. Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russell RG 1983 An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306:378-380.
18. Sabatini M, Boyce B, Aufdemorte T, Bonewald L, Mundy GR 1988 Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc Natl Acad Sci USA 85:5235-5239.
19. 3, and etidronate on bone. Bone 8:91-94.
20. Boyce BF, Aufdemorte TB, Garrett IR, Yates AJ, Mundy GR 1989 Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 125:1142-1150.
21. Dunnett CW 1955 A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50:1096-1121.
22. Fong Y, Moldawer LL, Marano M, Wei H, Barber A, Manogue K, Tracey KJ, Kuo G, Fischman DA, Cerami A, et al. 1989 Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol 256:R659-R665.
23. Ling PR, Schwarte JH, Bistrian BR 1997 Mechanisms of host wasting induced by administration of cytokines in rats. Am J Physiol 272:E333-E339.
24. Brown EM, Wilkson RE, Eastman RC, Pallotta J, Marynik SP 1982 Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 54:172-179.
25. Marie PJ, Lomri A, de Vernejoul MC, Morieux C, Graulet AM, Gueris J, Llach F 1989 Relationships between histomorphometric features of bone formation and bone cell characteristics in vitro in renal osteodystrophy. J Clin Endocrinol Metab 69:1166-1173.
26. 3 stimulates rat osteoblastic cells to release a soluble factor that increases osteoclastic bone resorption. J Clin Invest 80:425-429.
27. Arnaud CD, Sanchez SD 1990 The role of calcium in osteoporosis. Annu Rev Nutr 10:397-414.
28. Clark OH, Wilkes W, Siperstein AE, Duh QY 1991 Diagnosis and management of asymptomatic hyperparathyroidism: Safety, efficacy, and deficiencies in our knowledge. J Bone Miner Res 6:S135-S142; discussion 151-152.
29. O'Keefe RJ, Teot LA, Singh D, Puzas JE, Rosier RN, Hicks DG 1997 Osteoclasts constitutively express regulators of bone resorption: an immunohistochemical and in situ hybridization study. Lab Invest 76:457-465.
30. Raisz LG 1988 Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 318:818-828.
31. Ralston SH, Russell RG, Gowen M 1990 Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J Bone Miner Res 5:983-988.
32. Kimble RB, Matayoshi AB, Vannice JL, Kung VT, Williams C, Pacifici R 1995 Simultaneous block of interieukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early post-ovariectomy period. Endocrinology 136:3054-3061.
33. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW 1988 Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 2:706-709.
34. Arend WP, Dayer JM 1995 Inhibition or the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 38:151-160.
35. Togashi K, Takahashi N, Ando K, Tsukamoto Y, Marumo F 1990 Comparison of different parathyroid hormone radioimmunoassays in uremic patients with secondary hyperparathyroidism. Int J Artif Organs 13:77-82.
36. Mundy GR 1995 Primary hyperthyroidism. In: Mundy GR (ed.) Bone Remodeling and Its Disorders. Martin Dunitz Ltd., London, U.K., pp. 137-152.
37. Mason RS, Frankel T, Chan YL, Lissner D, Posen S 1984 Vitamin D conversion by sarcoid lymph node homogenate. Ann Intern Med 100:59-61.
38. 3 produced by cultured alveolar macrophages in sarcoidosis. J Clin Endocrinol Metab 60:960-966.
39. Sato K, Fujii Y, Kasono K, Tsushima T, Shizume K 1988 Production of interleukin-I alpha and a parathyroid hormone-like factor by a squamous cell carcinoma of the esophagus (EC-GI) derived from a patient with hypercalcemia. J Clin Endocrinol Metab 67:592-601.
40. Rosenblatt M, Caulfield MP, Fisher JE, Horiuchi N, McKee RL, Rodan SB, Thiede MA, Thompson DD, Seedor JG, Nutt RE, et al. 1988 A tumor-secreted protein associated with human hypercalcemia of malignancy. Biology and molecular biology. Ann NY Acad Sci 548:137-145.